Table 4.
Incidence rate of both clinically significant weight gain and extrapyramidal symptoms (EPS) on patients with antipsychotic treatment
| % Patients experiencing clinically significant weight gain | Sources | % Patients experiencing EPS | Sources | |
| Paliperidone ER | 3.3 | Invega PI, Janssen-Cilag International NV Turnhoutseweg 30 BE-2340 Beerse Belgium | 9.0% | [15] [21] [22] [23] |
| Risperidone | 9.0 | Risperdal PI, Janssen-Cilag Pharmaceutical SACI, Eirinis Avenue 56, 15121, Pefki, Athens, Greece | 9.0% | [15] |
| Olanzapine | 26.0 | Zyprexa PI, Eli Lilly Nederland B.V., Grootslag 1–5, NL-3991 RA Houten, The Netherlands. | 7.0% | [15] |
| Quetiapine | 17.0 | Seroquel PI, AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA | 3.0% | [15] |
| Ziprasidone | 6.0 | Geodon PI, Pfizer Hellas, Ltd, Mesogeion Avenue 243, 15451 Athens, Greece | 8.0% | [15] |
| Aripiprazole | 5.0 | Abilify PI, Otsuka Pharmaceutical Europe Ltd Hunton House Highbridge Business Park Oxford Road Uxbridge, Middlesex UB8 1HU United Kingdom | 8.0% | Assumed equal to ziprasidone |